Avid Bioservices Inc (CDMO)

[biopharm]

Immunoscore and Bernard A Fox ...hmmmm

It looks like John Stafford left Xencor JUST IN TIME as he just missed the arrival of Raphael Clynes (ex BMS)

June 8, 2017
Xencor Appoints Raphael Clynes, M.D., Ph.D., as Vice President of Translational Biology
https://www.firstwordpharma.com/node/1478610
_________________________

Novel technologies and emerging biomarkers for personalized cancer immunotherapy

Jianda Yuan1Email author, Priti S. Hegde2, Raphael Clynes3, Periklis G. Foukas4, 5, Alexandre Harari4, Thomas O. Kleen6, Pia Kvistborg7, Cristina Maccalli8, Holden T. Maecker9, David B. Page10, Harlan Robins11, Wenru Song12, Edward C. Stack13, Ena Wang14, Theresa L. Whiteside15, Yingdong Zhao16, Heinz Zwierzina17, Lisa H. Butterfield18 and Bernard A. Fox10Email author
Journal for ImmunoTherapy of Cancer20164:3
https://doi.org/10.1186/s40425-016-0107-3©; Yuan et al. 2016
Received: 19 November 2015Accepted: 5 January 2016Published: 19 January 2016

https://jitc.biomedcentral.com/articles/10.1186/s40425-016-0107-3

____________

There are others of significance (David Pave...Butterfield...etc etc) but now after showing ties from Ronin group nominees to CSM ..etc ...etc and just now back to Xencor with FC binding domains and Xencor - Merck agreements.....and now to Mr Clynes ex BMS...

A $2.9 Billion Medarex style like sell off transfer would seem possible by Ronin group .... I will continue to buy after seeing these puzzle pieces and all it says is Ronin group / John Stafford seem to know PS Targeting is worth much more than $2.9 Billion